A 70-year-old leukemia drug, 6-thioguanine, continues to unveil surprising insights as researchers identify how the protein NUDT5 influences patient responses in a way that traditional enzyme-blocking drugs did not anticipate.
- NUDT5 protein presence alters leukemia drug effectiveness.
- Removing NUDT5 protects cells from 6-thioguanine toxicity.
- New insights may explain patient response variability.
What happened
Scientists from the CeMM Research Center and partner institutions uncovered a surprising role of the protein NUDT5 in how cells respond to the leukemia drug 6-thioguanine (6-TG). They demonstrated that simply inhibiting NUDT5’s enzyme activity had little effect on the drug’s toxicity. However, eliminating the protein entirely made cells resistant to 6-TG treatment.
To reach these conclusions, researchers developed specialized small molecules known as degraders that remove NUDT5 from cells, rather than merely blocking its function. This approach revealed that NUDT5's physical presence, rather than its catalytic action, influences how cells react to the drug, marking a distinct departure from previous assumptions.
Why it feels good
This discovery illuminates an unexpected facet of cellular biology, showing that proteins may have critical functions beyond their known enzymatic activity. Understanding that NUDT5 acts as more than a chemical catalyst uncovers new layers of how leukemia drugs work, potentially impacting future treatment strategies.
Moreover, finding that NUDT5 absence protects cells from toxicity could help explain why leukemia treatments affect patients differently. The distinct roles of NUDT5 and a related protein, NUDT15, which influences drug sensitivity in the opposite manner, hint at a complex balance affecting therapy outcomes.
What to enjoy or watch next
Researchers will likely pursue the development of therapies that target NUDT5’s structural role in cells, which may offer improved approaches to leukemia treatment. Monitoring this protein’s function may also guide personalized medicine, helping clinicians predict and optimize patient responses to thiopurine drugs like 6-TG.
This study exemplifies the innovative methods used to explore protein functions beyond enzymatic activity, opening doors to novel drug design and molecular medicine advancements. Watching for follow-up clinical research and potential new drug candidates emerging from this work promises exciting progress in cancer treatment.